AZTR stock forecast, quote, news & analysis

Key Takeaways

• Azitra shares fell roughly 34.5% over the past 30 days, from a split-adjusted close of about $1.70 to approximately $1.11, despite a brief single-day surge on new cosmetic-program data.
• The decline reflects a prolonged slide into penny-stock territory and a 1-for-10 reverse stock split that became effective on October 26, 2026.
• A short-lived rally followed October 26 ex vivo results for ATR-COSF, which showed a roughly 50% reduction in the appearance of wrinkles after 48 hours.
• Over the trailing three months, the stock is down about 14.7%, having peaked near $1.86 in late August before trending lower through September and October.
• Clinical progress continued, including ATR-04 advancing to the second cohort of its Phase 1/2 study in EGFR inhibitor-associated skin rash.
• The company also suspended its at-the-market offering program and retains a small market capitalization near $9 million.
• For additional context on valuation and fundamentals, explore Azitra's Price Targets, Earnings, and Forecast pages.
• Explore Trending AI Robots to see how AI-driven trading strategies are monitoring tickers like AZTR.

Azitra (AZTR) Company Overview and Market Position

Azitra, Inc. is a clinical-stage biopharmaceutical company focused on precision dermatology. Headquartered in Branford, Connecticut, and founded in 2014, the company develops engineered proteins and topical live biotherapeutic products built on Staphylococcus epidermidis to treat skin diseases. Its lead therapeutic candidate, ATR-12, is in Phase 1b/2a development for Netherton syndrome, a rare genetic skin disorder. The company is also advancing ATR-04, a Fast Track-designated candidate for the skin rash associated with EGFR inhibitor cancer therapy, and ATR-01 for ichthyosis vulgaris. Azitra maintains a joint development agreement with Bayer and a proprietary microbial library of roughly 1,500 unique strains. Investors follow the stock for its rare-disease pipeline and dermatology platform, though as a pre-revenue, clinical-stage company it carries elevated financing and execution risk.

Azitra (AZTR) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, Azitra shares declined approximately 34.5%, moving from a split-adjusted close of $1.695 in late September to about $1.11 in late October. The path was far from linear: the stock slid steadily through the first half of October before a dramatic single-session rebound on October 26, followed by renewed selling pressure.

Looking at the broader three-month period, the stock is down roughly 14.7%, from a split-adjusted close near $1.30 in late July to about $1.11. The quarterly trend peaked in late August, when shares reached approximately $1.86, before a sustained retreat into September and October. All figures are adjusted for the 1-for-10 reverse stock split to provide a like-for-like comparison.

What Drove AZTR Stock Price in the Last 30 Days

The dominant driver was a prolonged decline that pushed the shares into penny-stock territory. In mid-October, the company announced a 1-for-10 reverse stock split, approved by the board on October 14 and effective October 26, reducing the issued share count from about 60.6 million to roughly 6.06 million. The move was aimed at regaining compliance with NYSE American continued-listing requirements, and it underscored the pressure the stock had faced.

On the clinical front, Azitra reported on October 1 that its Phase 1/2 trial of ATR-04 had completed the first cohort and that the safety review committee recommended advancing to cohort 2. On October 26, the company released ex vivo data for ATR-COSF, a cosmetic candidate, showing a roughly 50% reduction in the appearance of wrinkles 48 hours after a single application. The stock surged more than 100% intraday on the news, and the company separately announced the suspension of its at-the-market offering program. The rally proved short-lived, however, and shares pulled back sharply in subsequent sessions as investors weighed the early-stage nature of the data against the company's small market capitalization and financing needs.

What Drove AZTR Stock Performance Over the Last Quarter

The broader multi-month narrative centers on a clinical-stage company contending with a declining share price and a shrinking capital base. After reaching a late-August high near $1.86, the stock lost momentum through September and October as financing concerns mounted and the shares drifted toward a dollar threshold that triggered the reverse stock split. The capital-structure reset, combined with the early-stage ATR-COSF data and the ATR-04 cohort advancement, shaped the quarter's overall trajectory: sustained weakness punctuated by brief, news-driven spikes in volatility.

Trending AI Robots

Tickeron's Trending AI Robots page curates a selection of AI-powered trading bots from a broader marketplace of hundreds of bots that trade thousands of tickers. Only top-performing and most relevant bots appear in this section, offering traders a filtered view of strategies that have recently stood out. The bots vary widely in strategy, timeframe, and performance metrics, ranging from short-term momentum approaches to longer-horizon technical models. For investors tracking volatile small-cap names like AZTR, these tools can provide an additional, data-driven perspective on price action. Explore the page to see which AI strategies are currently gaining traction.

AZTR Stock Forecast Drivers: What Investors Should Watch Next

Several factors are likely to shape Azitra's share price in the months ahead. The company has said initial human clinical data for ATR-COSF is anticipated before the end of 2026, with additional details expected at the BIO-Europe conference in November. Continued enrollment and safety readouts from the ATR-04 Phase 1/2 cohort 2 will also be closely watched, as will progress on ATR-12 for Netherton syndrome. On the financial side, the company's small market capitalization, pre-revenue status, and need for additional funding remain key risk factors, particularly given the recent suspension of its at-the-market offering program and the possibility that it may pursue other financing transactions. Investors should monitor clinical milestones, regulatory developments, and capital-raising activity rather than relying on short-term price swings.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations